Castle Biosciences (CSTL) Revenue (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Revenue data on file, last reported at $83.7 million in Q1 2026.

• Quarterly Revenue fell 4.9% year-over-year to $83.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $339.9 million (down 2.06% YoY) and the FY2025 annual result came in at $344.2 million, up 3.66% from the prior year.
• Revenue declined to $83.7 million in Q1 2026 per CSTL's latest filing, from $87.0 million in the prior quarter.
• The five-year high for Revenue was $88.0 million in Q1 2025, with the low at $26.9 million in Q1 2022.
• Average Revenue over 5 years is $65.7 million, with a median of $73.0 million recorded in 2024.
• Year-over-year, Revenue surged 73.59% in 2024 and dropped 4.9% in 2026.
• Castle Biosciences' Revenue stood at $38.3 million in 2022, then surged by 72.47% to $66.1 million in 2023, then jumped by 30.54% to $86.3 million in 2024, then climbed by 0.81% to $87.0 million in 2025, then declined by 3.83% to $83.7 million in 2026.
• Business Quant data shows CSTL's Revenue at $83.7 million in Q1 2026, $87.0 million in Q4 2025, and $83.0 million in Q3 2025.